Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review

Bone

Volumn 58, Issue , 2014, Pages 126-135

  Eriksen, Erik F ^a   Díez Pérez, Adolfo ^b   Boonen, Steven ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Bisphosphonate; Bone mineral density; Fracture; Long term; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANGINA PECTORIS; ARTHRALGIA; BACKACHE; BONE DENSITY; BONE NECROSIS; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; COMORBIDITY; CONNECTIVE TISSUE DISEASE; CONSTIPATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLU LIKE SYNDROME; FRACTURE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INFORMATION RETRIEVAL; JAW OSTEONECROSIS; KIDNEY INJURY; KIDNEY TUBULE DAMAGE; LONG TERM CARE; LOW DRUG DOSE; MEDLINE; MUSCULOSKELETAL DISEASE; PATIENT MONITORING; PNEUMONIA; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

BISPHOSPHONATE; BONE MINERAL DENSITY; FRACTURE; LONG TERM; POSTMENOPAUSAL OSTEOPOROSIS;

BONE DENSITY; BONE REMODELING; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84887011575     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.09.023     Document Type: Review

References (63)

1. National Osteoporosis Foundation Clinician's guide to prevention and treatment of osteoporosis 2010, National Osteoporosis Foundation, [Available at: http://www.nof.org/files/nof/public/content/file/344/upload/159.pdf. Accessed: September 18, 2013].
2. National Institutes of Health Osteoporosis and Related Bone Diseases National Resource Centre Osteoporosis overview 2012, National Institutes of Health, [Available at: http://www.niams.nih.gov/Health_Info/Bone/Osteoporosis/overview.asp. Accessed: September 18, 2013].
3. Braithwaite R.S., Col N.F., Wong J.B. Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 2003, 51:364-370.
4. The National Hip Fracture Database National hip fracture database national report 2012 2012, The National Hip Fracture Database, [Available at: http://www.hqip.org.uk/assets/NCAPOP-Library/NCAPOP-2012-13/Hip-Fracture-Database-Audit-Report-pub-2012.pdf. Accessed: September 18, 2013.].
5. Pfeilschifter J., Cooper C., Watts N.B., Flahive J., Saag K.G., Adachi J.D., et al. Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women. Osteoporos Int 2012, 23:2179-2188.
6. Sorensen O.H., Crawford G.M., Mulder H., Hosking D.J., Gennari C., Mellstrom D., et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003, 32:120-126.
7. Akesson K. New approaches to pharmacological treatment of osteoporosis. Bull World Health Organ 2003, 81:657-664.
8. Black D.M., Thompson D.E., Bauer D.C., Ensrud K., Musliner T., Hochberg M.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000, 85:4118-4124.
9. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
10. Cummings S.R., San M.J., McClung M.R., Siris E.S., Eastell R., Reid I.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
11. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350:459-468.
12. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83-91.
13. Cooper C., Reginster J.Y., Cortet B., Diaz-Curiel M., Lorenc R.S., Kanis J.A., et al. Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr Med Res Opin 2012, 28:475-491.
14. Black D.M., Bauer D.C., Schwartz A.V., Cummings S.R., Rosen C.J. Continuing bisphosphonate treatment for osteoporosis-for whom and for how long?. N Engl J Med 2012, 366:2051-2053.
15. Whitaker M., Guo J., Kehoe T., Benson G. Bisphosphonates for osteoporosis-where do we go from here?. N Engl J Med 2012, 366:2048-2051.
16. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
17. Merck Sharp & Dohme Limited Fosamax® 10mg tablets summary of product characteristics. electronic Medicines Compendium Last updated: November 13, 2012. Available at:, [Accessed: September 18, 2013]. http://www.medicines.org.uk/emc/medicine/1175/SPC/Fosamax/.
18. Merck Sharp & Dohme Limited Fosamax® once weekly 70mg tablets: summary of product characteristics. electronic Medicines Compendium Last updated: October 22, 2012. Available at:, [Accessed: September 18, 2013]. http://www.medicines.org.uk/EMC/medicine/4115/SPC/Fosamax+Once+Weekly+70mg+Tablets/.
19. Novartis Pharmaceuticals UK Ltd. Aclasta® 5mg injection for infusion: summary of product characteristics. electronic Medicines Compendium Last updated: September 6, 2013. Available at:, [Accessed: September 18, 2013]. http://www.medicines.org.uk/EMC/medicine/18171/SPC/Aclasta+5+mg+solution+for+infusion/.
20. Roche Products Limited Bonviva® 3mg solution for injection: summary of product characteristics. electronic Medicines Compendium Last updated: January 3, 2013. Available at:, [Accessed: September 18, 2013]. http://www.medicines.org.uk/EMC/medicine/17546/SPC/Bonviva+3mg+3ml+solution+for+injection+in+pre-filled+syringe/.
21. Roche Products Limited Bonviva® 150mg film-coated tablets: summary of product characteristics. electronic Medicines Compendium Last updated: January 2, 2013. Available at:, [Accessed: September 18, 2013]. http://www.medicines.org.uk/EMC/medicine/16730/SPC/Bonviva+150mg+Film-Coated+Tablets/.
22. Warner Chilcott UK Limited Actonel® 5mg film-coated tablets: summary of product characteristics. electronic Medicines Compendium Last updated: June 19, 2013. Available at:, [Accessed: September 18, 2013]. http://www.medicines.org.uk/EMC/medicine/3340/SPC/Actonel+5mg+Film+Coated+Tablets/.
23. Warner Chilcott UK Limited Actonel® once a week 35mg film-coated tablets: summary of product characteristics. electronic Medicines Compendium Last updated: June 19, 2013. Available at:, [Accessed: September 18, 2013]. http://www.medicines.org.uk/EMC/medicine/11591/SPC/Actonel+Once+a+Week+35mg+film+coated+tablets./.
24. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
25. Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
26. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077-2082.
27. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344-1352.
28. Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., et al. Effects of continuing or stopping alendronate after 5years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296:2927-2938.
29. Black D.M., Reid I.R., Boonen S., Bucci-Rechtweg C., Cauley J.A., Cosman F., et al. The effect of 3 versus 6years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012, 27:243-254.
30. Mellstrom D.D., Sorensen O.H., Goemaere S., Roux C., Johnson T.D., Chines A.A. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 75:462-468.
31. Bianchi G., Czerwinski E., Kenwright A., Burdeska A., Recker R.R., Felsenberg D. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporos Int 2012, 23:1769-1778.
32. Eisman J.A., Civitelli R., Adami S., Czerwinski E., Recknor C., Prince R., et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008, 35:488-497.
33. Miller P.D., Recker R.R., Reginster J.Y., Riis B.J., Czerwinski E., Masanauskaite D., et al. Efficacy of monthly oral ibandronate is sustained over 5years: the MOBILE long-term extension study. Osteoporos Int 2012, 23:1747-1756.
34. Reginster J.Y., Adami S., Lakatos P., Greenwald M., Stepan J.J., Silverman S.L., et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2year results from the MOBILE study. Ann Rheum Dis 2006, 65:654-661.
35. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199.
36. Tonino R.P., Meunier P.J., Emkey R., Rodriguez-Portales J.A., Menkes C.J., Wasnich R.D., et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000, 85:3109-3115.
37. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437-1443.
38. Gallacher S.J., Dixon T. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Calcif Tissue Int 2010, 87:469-484.
39. Recker R.R., Armas L. The effect of antiresorptives on bone quality. Clin Orthop Relat Res 2011, 469:2207-2214.
40. Schwartz A.V., Bauer D.C., Cummings S.R., Cauley J.A., Ensrud K.E., Palermo L., et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010, 25:976-982.
41. Cosman F., Cauley J., Eastell R., Boonen S., Palermo L., Reid D.M., et al. Who is at highest risk for new vertebral fractures after 3years of annual zoledronic acid and who should remain on treatment?. J Bone Miner Res 2011, 26(S1). http://onlinelibrary.wiley.com/doi/10.1002/jbmr.v26.1s/issuetoc. [Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=ce715699-8143-4b48-ae65-d2e10fbc79c7. Accessed: September 18, 2013].
42. Li Z., Chines A.A., Meredith M.P. Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture?. J Musculoskelet Neuronal Interact 2004, 4:64-74.
43. Devogelaer J.P., Brown J.P., Burckhardt P., Meunier P.J., Goemaere S., Lippuner K., et al. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 2007, 18:1211-1218.
44. Garnero P., Hausherr E., Chapuy M.C., Marcelli C., Grandjean H., Muller C., et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996, 11:1531-1538.
45. Jamal S.A., Bauer D.C., Ensrud K.E., Cauley J.A., Hochberg M., Ishani A., et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007, 22:503-508.
46. US Food and Drug Administration FDA drug safety communication: new contraindication and updated warning on kidney impairment for Reclast (zoledronic acid) 2012, US Food and Drug Administration, [Available at: http://www.fda.gov/Drugs/DrugSafety/ucm270199.htm. Accessed: September 18, 2013].
47. Boonen S., Sellmeyer D.E., Lippuner K., Orlov-Morozov A., Abrams K., Mesenbrink P., et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008, 74:641-648.
48. Cummings S.R., Schwartz A.V., Black D.M. Alendronate and atrial fibrillation. N Engl J Med 2007, 356:1895-1896.
49. Barrett-Connor E., Swern A.S., Hustad C.M., Bone H.G., Liberman U.A., Papapoulos S., et al. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos Int 2012, 23:233-245.
50. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
51. Giusti A., Hamdy N.A., Papapoulos S.E. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010, 47:169-180.
52. Schilcher J., Michaelsson K., Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011, 364:1728-1737.
53. Schilcher J., Koeppen V., Ranstam J., Skripitz R., Michaelsson K., Aspenberg P. Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone 2013, 52:389-392.
54. Sutton R.A., Mumm S., Coburn S.P., Ericson K.L., Whyte M.P. "Atypical femoral fractures" during bisphosphonate exposure in adult hypophosphatasia. J Bone Miner Res 2012, 27:987-994.
55. Rizzoli R., Akesson K., Bouxsein M., Kanis J.A., Napoli N., Papapoulos S., et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011, 22:373-390.
56. Black D.M., Kelly M.P., Genant H.K., Palermo L., Eastell R., Bucci-Rechtweg C., et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362:1761-1771.
57. Burr D.B. Summary of ASBMR Task Force on ONJ. J Musculoskelet Neuronal Interact 2007, 7:354-355.
58. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491.
59. McClung M., Harris S.T., Miller P.D., Bauer D.C., Davison K.S., Dian L., et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013, 126:13-20.
60. Hannon R., Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 2000, 11(Suppl. 6):S30-S44.
61. Muraki S., Yamamoto S., Ishibashi H., Horiuchi T., Hosoi T., Orimo H., et al. Impact of degenerative spinal diseases on bone mineral density of the lumbar spine in elderly women. Osteoporos Int 2004, 15:724-728.
62. Boonen S., Ferrari S., Miller P.D., Eriksen E.F., Sambrook P.N., Compston J., et al. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective. J Bone Miner Res 2012, 27:963-974.
63. Miller P.D. The kidney and bisphosphonates. Bone 2011, 49:77-81.